Aim: The human parechovirus (HPeV) is an increasingly recognised cause of sepsis and central nervous system infection in young infants for which there are limited long-term outcome data. We aimed to assess neurodevelopmental outcome and quality of life in infants following hospitalised HPeV infection. Methods: This cohort study was a 12-month follow-up of infants who were hospitalised with confirmed HPeV infection at the Sydney Children's Hospitals Network during an outbreak in Sydney in 2013. Telephone interviews were conducted with parents/guardians. We administered standardised questionnaires, including: Ages and Stages Questionnaire (ASQ), Liverpool Outcome Score-follow-up, Pediatric Quality of Life Inventory (PedsQL) Infant scales and Short-Form health survey (SF-12). Results: We followed up 46 of 79 infants (58%) aged between 12 and 16 months who had been hospitalised with HPeV infection; 19% showed significant concern in developmental attainment (ASQ3 score <2 standard deviation below population mean), and 50% showed some concern (<1 standard deviation below mean). ASQ3 developmental outcome was associated with the presence of neurodevelopmental sequelae (lower total Liverpool Outcome Score) and poorer health-related quality of life (HRQOL) in physical functioning (PedsQL physical component score), but not overall HRQOL (total PedsQL score) or parental HRQOL (SF-12 scores). No significant associations were identified between clinical or laboratory features during acute hospitalisation and adverse outcome on ASQ3. Conclusions: A high proportion of infants show developmental concern at 12-month follow-up post-hospitalisation with HPeV infection. Clinical features during hospitalisation were not associated with adverse outcomes at 12 months. These results suggest that careful follow-up of young infants hospitalised with HPeV disease may be warranted.
1 The human parechovirus (HPeV) is an increasingly recognised cause of sepsis and central nervous system (CNS) infection in young children. 2 HPeV encephalitis, the most severe form of HPeV CNS disease, can result in significant neurological morbidity, including cerebral palsy and epilepsy.
What this paper adds
1 This is the first study to systematically study the outcome of hospitalised HPeV infection in infants using standardised outcome measures. 2 A high proportion of infants aged 12-16 months had concerns identified in development 12 months following hospitalised HPeV infection, one-fifth with significant concern (developmental attainment ≤ 2standard deviation below the population mean). Significant concern was most frequently identified in gross motor and problem-solving domains. 3 No specific clinical or diagnostic features during acute hospitalisation were associated with developmental outcome, although the majority of children did not have adequate neurological testing to categorise the nature of their CNS infection.
The human parechovirus genotype 3 (HPeV3) is an increasingly recognised cause of sepsis and central nervous system (CNS) infection in young children. [1] [2] [3] [4] Despite a number of publications describing the frequency and clinical features of HPeV3 infection, [1] [2] [3] [4] [5] [6] [7] there are limited outcome data reported. A number standardised measures. We and others have reported a high prevalence of neurological morbidity in survivors of infant HPeV encephalitis, 10, 11 which represents the most severe form of HPeV CNS disease. However, the outcome of all forms of HPeV3 infection causing hospitalisation in infants is poorly defined. Although HPeV can be detected in the cerebrospinal fluid (CSF) in many hospitalised infants, the nature of the CNS infection is difficult to characterise due to challenges in applying encephalitis case definitions in this age group, 7, 12, 13 particularly because of the nonspecific features of encephalopathy, the low frequency of comprehensive testing (neuroimaging, electroencephalograms (EEG)) and the characteristic lack of CSF pleocytosis. 11, 14 Studying the long-term outcome of all forms of hospitalised HPeV infection is therefore important. An outbreak of HPeV3 infection occurred in the southern hemisphere in spring/summer of 2013-2014 in New South Wales, Australia, causing a large number of infants to be hospitalised. 15 The majority of infants in this series were admitted to one of the two hospitals in the Sydney Children's Hospitals Network (SCHN), the Children's Hospital at Westmead (CHW) or Sydney Children's Hospital (SCH), Randwick. Here, we sought to assess the developmental progress, quality of life and neurological function of these infants at 12 months following their admission to hospital with HPeV disease.
Methods Participants
Between December 2014 and February 2015, we contacted the parents/guardians of the 79 infants from the series reported by Khatami et al. 12 who were admitted to the SCHN between October 2013 and January 2014 with laboratory-proven HPeV infection (HPeV RNA detected by reverse transcription polymerase chain reaction (RT-PCR) from any acute specimen). Questionnaires were sent to parents/guardians and then completed with one of the study investigators in a telephone interview. Telephone interviews were undertaken to maximise the participant response rate. Interviewers ensured questionnaire completion. Where parents sought question clarification, interviewers were instructed not to provide their own interpretation, repeat questions verbatim and encourage parents to give 'their response'. Clinical data from the acute hospital admission were collected by retrospective chart review of included infants and have been previously reported. 12 A subset of these acute variables was selected for this outcome analysis, decided upon by the study investigators (Table 2) . To facilitate analysis, continuous variables (e.g. fever, liver function tests) were categorised as dichotomous.
Outcome measures
The primary outcome measure was developmental outcome at 12 months post-discharge using the age-appropriate Ages and Stages Questionnaire Version 3 (ASQ3; http://agesandstages. com/). ASQ3 is a series of 21 developmental screening questionnaires completed by parents/guardians of children aged between 1 and 66 months (each questionnaire covers between 1 and 6 months) to determine the level of developmental attainment. The questions are stratified into five domains, including:
communication, gross motor, fine motor, problem-solving and adaptive skills. An additional section assesses the overall health and development of the child. Questionnaire results were scored by two study investigators (PN Britton and G Khandaker) using the ASQ3 age-specific scoring sheet. We categorised the ASQ3 responses as 'significant', 'some' or 'no' developmental concern according to questionnaire-defined subscale cut-off scores (quantitative results: 'significant' concern corresponds to the ASQ cutoff score set at >2 standard deviations (SD) below the population mean of developmental attainment; 'some' concern corresponds to the cut-off score set at >1 and ≤2 SD). Where concern regarding developmental attainment was identified in the overall responses section of the ASQ (qualitative results), the response was categorised as 'some concern'. Where the parents only expressed concerns about health issues not directly relevant to developmental attainment (e.g. recurrent infections), these were not categorised as 'some' concern. During the telephone interview, we also administered the the Liverpool Outcome Score-follow-up (LOS-f/up, 2013), the Pediatric Quality of Life Inventory (PedsQL)-Infant Scales (http:// www.pedsql.org/) and the Short-Form health survey (SF-12).
Results from these scores were our secondary outcome measures. The LOS-f/up is a 15-item questionnaire that assesses neurological function in children following encephalitis (http://www.path. org/vaccineresources/details.php?i=677). 16, 17 For each item, the child is assigned a score out of 5. The LOS can be reported as a total score out of 75 or, alternatively, as a summary score assigned as the lowest score for any single item. We categorised the LOS-f/up summary scores as: 1-2, severe neurological sequelae; 3-4, mild to moderate sequelae; 5, nil sequelae. The PedsQL infant is an age-specific generic questionnaire (http://www. pedsql.org/) designed to measure health-related quality of life (HRQOL) in children aged between 13 and 24 months. It assesses the presence/frequency of stated 'problems' in five dimensions (physical functioning, physical symptoms, emotional functioning, social functioning and cognitive functioning) on a 5-point Likert scale. The PedsQL responses are assigned three scores out of 100: a total health score, a psychosocial health score and a physical health score. A higher score indicates better HRQOL. The SF-12 is a 12-item questionnaire that assesses HRQOL amongst adultshere, the parents/guardians of the infants followed up for this study. It is scored online (http://www.sf-36.org/demos/SF-12. html), giving a quantitative measure of HRQOL in two dimensions: the physical component score (PCS) and the mental component score (MCS). Scores range from 0 to 100, with a higher score indicating a higher HRQOL.
Analysis
We analysed the results of the outcome questionnaires descriptively and stratified the results of the LOS-f/up, PedsQL and SF-12 questionnaires by the ASQ3 results. We performed a univariate comparison of the acute clinical features of the infants according to their 12-month outcomes determined using the ASQ3. Data were analysed using Microsoft Excel, 2010 and SPSS version 22 (SPSS Inc., Chicago, IL, USA). Approval for this study was obtained from the SCHN Human Research Ethics Committee (approval number 13/SCHN/191).
Results
Seventy-nine infants were admitted to hospitals in the SCHN with confirmed HPeV infection during the 2013/2014 outbreak. Follow-up was completed on 42 infants, including 26 from CHW and 16 from SCH. Partially completed ASQ3 questionnaire responses were received from an additional four. There were no deaths reported between discharge from hospital and follow-up. The primary reason for loss to follow-up was inability to contact the parent/guardian of potential participants.
To determine if the infants in the follow-up cohort were representative of the complete study cohort, we compared the acute clinical features of those children with follow-up data available to those we were unable to follow up. We found no statistically significant differences between the two groups in the frequency of key demographic and clinical features (Table S1 , Supporting Information). There were trends of a higher proportion of females in the follow-up cohort (57% vs. 36% not f/up; P value = 0.08) and a higher proportion of children in whom neuroimaging was performed (cranial ultrasound 23% vs. 9% not f/up (P = 0.09); magnetic resonance imaging (MRI) brain 15% vs. 3% (P = 0.08). This cohort includes four infants with confirmed HPeV encephalitis that have been recruited into a prospective, cohort study for childhood encephalitis study (the Australian Childhood Encephalitis study). Their 12-month outcomes (ASQ and clinical) have been already reported. 11 To our knowledge, none of the infants had received formal developmental assessment at the time of our follow-up telephone interviews. Amongst the infants with complete ASQ3 questionnaires, all 42 children were diagnosed during their acute admission with a 'sepsis-like' illness. On retrospective review, five children would meet the case definition 18 for a diagnosis of encephalitis (two of:
seizures, abnormal EEG or abnormal MRI). Of the remaining 37 children, none had an EEG performed, and in 5, an MRI was performed that was reported to be normal or with minor nonspecific findings. We identified concerns with developmental attainment in 50% (21/42), 19% (8/42) of whom showed significant concern and a further 31% (13/42) who showed some concern (Fig. 1) . Where significant concern was identified, it was most frequent in the gross motor (5/42; 12%) and problem-solving (3/44; 7%) domains. In the eight infants showing significant concern, only one had required further hospitalisation (this was due to subsequent enterovirus meningitis); five showed significant or some concern in two or more domains and seven qualitative concern in one or more areas (gross motor, hearing, behaviour, staring episodes). Of importance, seven of these eight infants with significant concern had been assessed as being without neurological sequelae at discharge or at short-term follow-up. For the remaining infant, there was no information available regarding shortterm outcome. Of the five children who would meet a case definition for encephalitis, three showed developmental concern at 12 months -one with significant concern, two with some concern. Four infants showed qualitative concern in the overall response section of the ASQ3 but did not show any developmental concern in the quantitative results (developmental domain subscales).
Using the LOS-f/up questionnaire, 39% (17/44) of infants followed up showed some neurological sequelae, 2 infants with severe neurological sequelae identified in individual LOS questions (gross motor function) and 15 with mild to moderate sequelae (communication, motor function and behaviour) (Fig. 2) . None of the infants had ongoing seizures.
In Table 1 , we show the LOS-f/up, PedsQL infant and SF-12 scores stratified by the results of the ASQ3. Infants with developmental concern identified on ASQ3 had significantly lower mean LOS-f/up total score and mean PedsQL PCS compared to those without any developmental concern. We observed no association between ASQ3 scores and mean SF-12 results or mean PedsQL psychosocial component and total scores. Table 2 shows the univariate comparison of the available acute clinical and diagnostic features of infants hospitalised with HPeV infection according to their 12-month outcome, which was determined using the ASQ3. We did not identify any acute clinical variable that was associated with adverse developmental outcome. A trend to increased length of hospital stay was noted in infants with significant concerns identified by ASQ3.
Discussion
This is the first study to systematically report the long-term outcome of HPeV infection causing hospitalisation. We have measured neurodevelopmental outcomes and HRQOL using validated, standardised tools and identified that a high proportion of infants showed developmental concern at 1-year follow-up posthospitalisation when aged between 12 and 16 months; half of the infants show some concern and one-fifth significant concern. We have shown that the concern regarding developmental attainment is most prominent in the gross motor and problem-solving domains. We have also demonstrated that these findings Fig. 1 Developmental outcome assessed using the Ages and Stages Questionnaire (ASQ3) in infants 12 months following hospitalisation with human parechovirus infection. Shown is a bar graph of the total score and subscale scores of ASQ3 indicating ( ), no concern; ( ), some concern (1-2 standard deviation (SD)); or ( ), significant concern (<2 SD) (n = 42).
correspond to the presence of neurodevelopmental sequelae as measured using the LOS and a poorer HRQOL in terms of physical functioning/symptoms measured using the PedsQL infant scales. However, we were unable to identify any acute clinical or diagnostic features from these children's original hospitalisation that was associated with these outcomes, although we did note a trend towards longer total length of stay in hospital amongst infants with significant developmental concern. A probable explanation for this is that acute clinical data were collected retrospectively, and we were unable to collect all potentially relevant clinical and diagnostic information, and some important investigations (e.g. MRI) were not performed on most infants. We were surprised not to identify neuroimaging markers in the acute admission that would predict adverse outcome because previous studies -including our own study of childhood encephalitis (Australian Childhood Encephalitis study) -have suggested that neuroimaging (MRI) changes correspond with neurological morbidity. 10, 11, 19 Amongst our cohort, MRI was performed infrequently (7/42), although HPeV was identified from the CSF in the majority (91%; 31/34 tested). Cranial US was performed more often (11/42); however, we have shown that this modality can be normal even in children with significant brain MRI abnormalities. 11 Cases of HPeV infection have been described where full recovery has been described despite acute MRI abnormalities; however, these cases have not been assessed using standardised outcome measures. 2 A further concern is that many infants in our cohort with significant concern in neurodevelopment had been previously described as having 'recovered fully'. Given the possible importance of MRI findings in identifying infants with HPeV CNS infection at risk of adverse neurodevelopmental outcome, 10, 11, 19 we suggest that a low threshold be adopted for the performance of MRI in infants with hospitalised HPeV disease. 19 Given the absence of any acute clinical features associated with the outcome in this study, we cannot give a definitive threshold to guide clinicians further. However, additional clinical factors of potential concern from the literature include: very young children (aged <4 weeks), ex-prematurity, seizures and other end-organ disease. 10, 11, 19 Our findings suggest that HPeV infection that requires hospitalisation may result in an adverse motor development. We have reported that children with confirmed HPeV encephalitis in early life may go on to develop cerebral palsy. 11 Furthermore, the characteristic MRI in this condition is of symmetrical white matter diffusion restriction 2, 4, 10, 11, 20, 21 . We, and others, have noted the overlap of these features with those associated with hypoxic-ischaemic injury in neonates who are at high risk of cerebral palsy. 11, 22 A further important contribution is the recently published autopsy findings from two cases of fatal Table 1 Univariate comparison of total Liverpool Outcome Scores (LOS), infant and parent/guardian health-related quality of life (Pediatric Quality of Life Inventory (PedsQL) and Short-Form health survey (SF-12)) with developmental attainment as determined using Ages and Stages Questionnaire (ASQ3) in infants 12 months post-hospitalisation following human parechovirus infection ASQ nil concern (n = 21) ASQ some concern (n = 13) ASQ significant concern (n = 8) P value (ASQ concern vs. no concern)
P value (ASQ significant concern vs. no concern)
LOS total mean score (SD) 74. parechovirus encephalitis. 23 These show localisation of HPeV3 to meningeal cells and blood vessels in the meninges and lung, but not to brain parenchyma, using in situ hybridisation. 23 The authors have suggested that CNS tissue damage may result from dysfunction of infected blood vasculature resulting in impaired blood flow, and hypothesised that other organ dysfunction in severe parechovirus infection might similarly be a result of a systemic vasculopathy. 23 The pathogenesis of HPeV CNS infection requires further elucidation; however, we suggest that the possible outcome phenotype identified in this study would concur with a vasculopathic process causing localised hypoxicischaemic injury. We acknowledge some inherent limitations in this study. Firstly, the ASQ is designed as a developmental screening tool. Table 2 Univariate comparison of the clinical and diagnostic features during acute admission with parechovirus infection with developmental attainment determined using the Ages and Stages Questionnaire (ASQ3) 12 months following admission ASQ nil concern (n = 21), n (%) ASQ some concern (n = 13), n (%) ASQ significant concern (n = 8), n (%) P value (ASQ concern vs. no concern)
P value (ASQ significant concern vs. no concern) 1.00 0.71 †There were three cases of late prematurity in this cohort: One 36 weeks gestation at birth -'significant concern' at follow-up; one 35 weeks -'some concern' at follow-up; one 33 weeks -'some concern' at follow-up. All were assessed using age-appropriate ASQ even when corrected for premature birth.
‡Human parechovirus (HPeV) was identified from cerebrospinal fluid (CSF) in 28 infants (67%); 12 infants did not have CSF tested for HPeV; and only 2 infants were tested and were negative. HPeV was identified from stool or rectal swabs in 26 (62%), including 12 (29%) infants in whom CSF was not tested or was negative. HPeV reverse transcription polymerase chain reaction (RT-PCR) was identified from nasopharyngeal aspirate or throat swab in four (10%), including three infants in whom CSF was not tested or was negative. RT-PCR for HPeV was not performed on blood in any children. §Coagulopathy defined as an elevated international normalised ratio. ¶Hepatitis defined as an aspartate aminotransferase or alanine aminotransferase ≥ twice the upper limit of normal. † †Significant respiratory support defined as requirement for mechanical ventilation or non-invasive respiratory support, including continuous positive airway pressure. -, Test not performed; EEG, electroencephalogram; ICU, intensive care unit; MRI, magnetic resonance imaging; SD, standard deviation.
The ASQ's own validation data show a sensitivity and specificity of 86.1% and 85.6%, respectively, compared to more definitive developmental assessment. It is possible some of these children have been misclassified because of using the ASQ. Secondly, the LOS at follow-up questionnaire has been used in this cohort at the lower end of the age range in which it has been previously used and validated. Furthermore, the age at which developmental attainment has been assessed in this cohort is still young (12-16 months) . Definitive developmental outcome in these children cannot be inferred from this assessment because of their young age. In addition, our study had a 42% loss to follow-up. This poses a possible 'selection bias' in our findings, although we would again note that we found no significant differences in collected data between those followed up and not followed up. These limitations should result in some caution when interpreting the results of this study, particularly with regards to the absolute proportions of infants with developmental concern and adverse neurological outcomes. We would, however, emphasise that the findings presented here are sufficient to conclude that it cannot be assumed that hospitalised HPeV infection in infants is associated with a benign neurodevelopmental outcome. Clearly, there is a need for ongoing followup of this cohort to address the remaining knowledge gaps and to facilitate early intervention where required. Ideally, we would advocate that assessment occur between the ages of 3 and 5 years using a comprehensive developmental assessment tool (e.g. Bayley Scales of Infant and Toddler Development or Griffith Mental Development Scales) and inclusion of a control group.
Conclusions
We have presented the 12-month outcome of infants hospitalised with parechovirus infection in Sydney, Australia. We have identified a high prevalence of adverse developmental outcome amongst these infants. These results remain preliminary; however, pending future research, they support a precautionary approach to the follow-up of infants admitted to hospital with parechovirus disease. We recommend careful follow-up with a clinician experienced in child development until, at least, school entry. Where concern is identified or expressed, a low threshold should be adopted for referral for paediatric assessment.
